X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Viropro cGMP Biomanufacturing Facility, Malaysia

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Asia, Projects

Alpha Biologics, a contract biomanufacturing service provider, commissioned a new cGMP biomanufacturing plant in April 2010. The plant, located at the Penang Biotech Park in Malaysia is dedicated to the production of mammalian cell secreted proteins.

The plant broke ground in June 2006 and was built at an investment of $18m between 2007 and 2009. It was constructed in compliance with the FDA and EMEA guidelines.

The design incorporates a flexible layout that was reviewed by the Centre of Drug Evaluation and Research (CDER) at the FDA and declared suitable for clinical studies and early market product development.

The facility has multiple rooms and functions that enable parallel working processes, thus reducing timelines and the eventual cost to the customer.

In the first quarter of 2010, Alpha Biologics was acquired by Viropro, a research and manufacturing service contractor based in Nevada. The acquisition was completed on 22 February 2010 for a consideration of $21m.

The facility is due to obtain accreditation under the Pharmaceutical Inspection Cooperation Scheme. The accreditation process is expected to commence in the next few months.

Facility

 

The plant spreads over an area of 5,000m² and accommodates upstream process development laboratories, cGMP manufacturing space and support areas.

“The design incorporates a flexible layout that was reviewed by the CDER.”

The manufacturing space includes process suites, isolation suites, two independent DSP suites and separate final filtration / viral removal suites. Class 10,000 (Grade C) process suites with Class 100,000 (Grade D) support areas are encircled by a return corridor, which provides visitors an inside view through the windows.

Waste material is disposed of via the return corridor, avoiding their crossover with clean items.

There are three isolation suites used for USP-cell banking and associated operations. These suites are equipped to develop master cell banks (MCB) and working cell banks (WCB), bioreactor seed or small scale product manufacturing for pre-clinical studies.

The bioreactor suite is equipped with seven bioreactors with capacities ranging from 10l to 500l (3 x 10l, 1 x 70l, 2 x 250l, 1 x 500l). The bioreactors can be operated in batch, fed-batch or perfusion mode – and the flexible design of the facility allows utilisation of bioreactors in different combinations in a closed system. There are two recovery suites for cell harvest clarification, with medium to large scale ultra filtration capabilities.

There are two purification suites for pre- and post-virus processing, equipped with chromatography and ultra-filtration skids and dedicated cold rooms. The final filtration / viral removal suites are installed with chromatography for final filtration and bulk aliquotting.

Upstream process development laboratories are located on the ground floor of the facility and are designed to allow the scale up of cell cultures in bioreactors of different capacity. Work in the upstream process laboratories is carried out with identical equipment to the cCMP manufacturing suites.

The bioreactor suite has three bioreactors of 10l, 70l and 250l capacities, all operable on batch, fed batch and perfusion mode. Purification equipment includes both small and large scale chromatography and ultra-filtration systems.

This use of identical equipment ensures smooth technical transfer to cGMP manufacture, with a few operational changes and cleaning validation to reduce normal timelines for process development and cGMP manufacture. This, in turn, results in major cost savings for clients.

“The bioreactor suite has three bioreactors of 10l, 70l and 250l capacities.”

The facility also includes microbiology and quality control laboratories for environmental testing, analytical laboratories for in-process assays and a buffer preparation unit with 50l, 120l, 250l and 1000l preparation vessels.

There is also a cell bank and product storage zone for -20°C, -80°C and liquid and vapour phase nitrogen storage.

Additional equipment in this part of the plant includes process washing machines, sterilising autoclaves and CIP station.

Production

 

The facility is dedicated to the production of proteins secreted from mammalian cell cultures, including monoclonal antibodies and recombinant proteins. Hybridoma, CHO and NSO cell lines are the most common cell types used.

Prior to cGMP manufacturing, the facility develops cell lines and master and manufacturing working cell banks. The facility also produces supernatants, membrane fractions or other product options.

The facility has been designed to combine bioreactors with perfusion technology whenever required, to increase production capacity by 20 fold. This combination of stirred tank processes and perfusion enables ultra-efficient production of secreted protein for pre-clinical or clinical trial studies or early market use.

Tags: Asia Pacific
Previous Post

Aventis Enoxaparin Sodium Manufacturing Plant, Singapore

Next Post

AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia, United Kingdom

Related Posts

Indian Pharmaceutical Industry In 2021 And The Road Ahead
Asia

Indian Pharmaceutical Industry In 2021 And The Road Ahead

24th January 2022
Pfizer, Moderna & AstraZeneca - Their COVID-19 vaccine comparison
Asia

India crosses historic one billion COVID-19 vaccine milestone

26th October 2021
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
Asia

UAE approves use of Sinopharm vaccine for children aged between 3 and 17 years

5th August 2021
Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market
Asia

Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market

17th May 2021
India authorises DRDO's oxygen dependence-lowering drug for Covid-19
Asia

India authorises DRDO’s oxygen dependence-lowering drug for Covid-19

11th May 2021
New dates for MEDICAL FAIR THAILAND with move to 2022
Asia

New dates for MEDICAL FAIR THAILAND with move to 2022

30th April 2021
Next Post

AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia, United Kingdom

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In